

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

19 Jun 2026

### Comparison of the Effectiveness of Prophylactic Two Different Doses of Dexmedetomidine in Prevention of Shivering During Regional Anesthesia in Cesarean Section

#### Protocol summary

##### Study aim

The Survey of Prophylactic Two Different Doses of Dexmedetomidine in Prevention of Shivering During Regional Anesthesia in Cesarean Section

##### Design

This study was conducted in parallel ,double-blind,randomized,60 patients who were in the phase 3 trial were designed.

##### Settings and conduct

Pregnant women referred to Alzahra Hospital and Shahid Beheshti Hospital who underwent spinal anesthesia were divided into three random groups. The first group received 2.5 µg / kg dexmedetomidine The second group received 5 µg / kg dexmedetomidine and the third group received normal saline. Clinical participant, evaluator and analyzer do not understand type of drug and after decoding b, a and c code is decoded by researcher

##### Participants/Inclusion and exclusion criteria

Inclusion criteria :1-Pregnant women in the age range18-45 2- Anesthesiologists American Society of (ASA) degree2and3 candidate for cesarean section 3- Patient consent to participate in the study Exclusion criteria:En A history of hypersensitivity to alpha adrenergic drug- Liver Patients -Bradycardia history -2nd or 3rd degree AV block Vascular problems- Type 2 diabetes- Hypovolemia- Taking vasodilator or medications that change the body's central temperature- Drug use

##### Intervention groups

Informed consent was obtained from the parents of the patients first. After the patients were placed on the operating bed and after connecting standard monitoring including pulse oximeter, barometer, ECG and baseline vital signs, then the intervention group A received2.5 µg / kg dexmedetomidine and Intervention group B received 5 µg / kg dexmedetomidine and the control group received normal saline syringe.

#### Main outcome variables

Shivering

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20160307026950N17**

Registration date: **2020-03-19, 1398/12/29**

Registration timing: **retrospective**

Last update: **2020-03-19, 1398/12/29**

Update count: **0**

##### Registration date

2020-03-19, 1398/12/29

##### Registrant information

##### Name

Behzad Nazemroaya

##### Name of organization / entity

Isfahan University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 3212 3543

##### Email address

behzad\_nazem@med.mui.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-02-02, 1398/11/13

##### Expected recruitment end date

2020-03-19, 1398/12/29

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparison of the Effectiveness of Prophylactic Two Different Doses of Dexmedetomidine in Prevention of Shivering During Regional Anesthesia in Cesarean Section

**Public title**

The Survey of Prophylactic Two Different Doses of Dexmedetomidine in Prevention of Shivering During Regional Anesthesia in Cesarean Section

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Pregnant women in the age range 18-45 2-3 degree candidate for cesarean section Patient consent to participate in the study

**Exclusion criteria:**

A history of hypersensitivity to alpha adrenergic drug Liver Patients Bradycardia history 2nd or 3rd degree AV block Vascular problems Type 2 diabetes Hypovolemia Taking vasodilator or medications that change the body's central temperature Drug use

**Age**

From **18 years** old to **45 years** old

**Gender**

Female

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Patients are randomly assigned to three groups A, B, C using the Random Allocation computer software

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

The drug and placebo are prepared in one form and in the form of a volume in the syringe by the researcher, and the hemodynamic changes are monitored and recorded, so the attending and the clinical caregiver and the evaluator and data analyser do not understand the type of medication and the investigator deciphers the codes after data analysis.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Isfahan University of Medical Sciences

**Street address**

Hezar jarib Street

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174673461

**Approval date**

2020-02-01, 1398/11/12

**Ethics committee reference number**

IR.MUI.MED.REC.1398.558

**Health conditions studied****1****Description of health condition studied**

Shivering

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

Shivering

**Timepoint**

Recovery Duration

**Method of measurement**

Using the Grassi and Mahajan criterion

**2****Description**

Central temperature

**Timepoint**

At the base time; after the procedure and then every 15 minutes until discharge of recovery.

**Method of measurement**

Tympanic thermometer

**3****Description**

Temperature of Peripheral

**Timepoint**

At the base time; after the procedure and then every 15 minutes until discharge of recovery.

**Method of measurement**

Thermometer Skin

**4**

**Description**

The level of sedation

**Timepoint**

At the base time; after the procedure and then every 15 minutes until discharge of recovery.

**Method of measurement**

Using the Ramsay Sedation Scale

**5**

**Description**

Severity of Pain

**Timepoint**

At of recovery. the base time; after the procedure and then every 15 minutes until discharge

**Method of measurement**

Using the Visual Analogue Scale

**6**

**Description**

Systolic blood pressure

**Timepoint**

At the base time; after the procedure and then every 15 minutes until discharge of recovery.

**Method of measurement**

Non invasive blood pressure measurement

**7**

**Description**

Diastolic blood pressure

**Timepoint**

At the base time; after the procedure and then every 15 minutes until discharge of recovery

**Method of measurement**

Non invasive blood pressure measurement

**8**

**Description**

Oxygen saturation

**Timepoint**

At the base time; after the procedure and then every 15 minutes until discharge of recovery

**Method of measurement**

Pulse oximetry device

**9**

**Description**

Heart Rate

**Timepoint**

At the base time; after the procedure and then every 15

minutes until discharge of recovery.

**Method of measurement**

Heart monitoring device

**10**

**Description**

Mean Arterial Blood Pressure

**Timepoint**

At the base time; after the procedure and then every 15 minutes until discharge of recovery.

**Method of measurement**

Non invasive blood pressure measurement

**11**

**Description**

Duration of stay in recovery

**Timepoint**

From recovery admission to recovery discharge

**Method of measurement**

Watch or clock

**Secondary outcomes**

**1**

**Description**

Nausea

**Timepoint**

Duration of stay in recovery

**Method of measurement**

Questionnaire

**2**

**Description**

Vomiting

**Timepoint**

Duration of stay in recovery

**Method of measurement**

Questionnaire

**3**

**Description**

Itching

**Timepoint**

Duration of stay in recovery

**Method of measurement**

Questionnaire

**4**

**Description**

Usage of Atropine

**Timepoint**

From the beginning of the operation to the end of recovery

**Method of measurement**

Anesthesia Technician Asked About Drug Use

## 5

### **Description**

Usage of Pethidine

### **Timepoint**

Duration of stay in recovery

### **Method of measurement**

Anesthesia Technician Asked About Drug Use

## 6

### **Description**

Usage of Ephedrine

### **Timepoint**

From the beginning of the operation to the end of recovery

### **Method of measurement**

Anesthesia Technician Asked About Drug Use

## **Intervention groups**

### 1

#### **Description**

Intervention group A: informed consent from patients first. After patients are placed on operating room bed, standard monitoring including pulse oximeter, barometer, ECG and baseline vital signs Group A = 2.5 µg / kg intravenous dexmedetomidine is given immediately after induction of anesthesia, and mean arterial blood pressure, heart rate, systolic and diastolic blood pressure, and other variables are considered at the desired times.

#### **Category**

Prevention

### 2

#### **Description**

Intervention group B: informed consent from patients first. After patients are placed on operating room bed, standard monitoring including pulse oximeter, barometer, ECG and baseline vital signs Group A = 5 µg / kg intravenous dexmedetomidine is given immediately after induction of anesthesia, and mean arterial blood pressure, heart rate, systolic and diastolic blood pressure, and other variables are considered at the desired times.

#### **Category**

Prevention

### 3

#### **Description**

Control group: informed consent from patients is first obtained. After placing the patients on the operating room bed, standard monitoring including pulse oximeter, barometer, ECG and baseline vital signs are recorded. Intravenous saline is given immediately after induction of anesthesia and moderate arterial blood pressure, heart rate, systolic and diastolic blood pressure, and other variables are considered at the desired time.

#### **Category**

Prevention

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Al-zahra hospital

##### **Full name of responsible person**

Behzad Nazemroaya

##### **Street address**

Soffeh boulevard, Shahid Keshvari highway

##### **City**

Isfahan

##### **Province**

Isfahan

##### **Postal code**

8174675731

##### **Phone**

+98 31 3620 2020

##### **Email**

behzad\_nazem@med.mui.ac.ir

### 2

#### **Recruitment center**

##### **Name of recruitment center**

Shahid Beheshti Hospital

##### **Full name of responsible person**

Behzad Nazemroaya

##### **Street address**

West Shahid Motahari Street

##### **City**

Isfahan

##### **Province**

Isfahan

##### **Postal code**

8184851153

##### **Phone**

+98 31 3236 7001

##### **Email**

behzad\_nazem@med.mui.ac.ir

## **Sponsors / Funding sources**

### 1

#### **Sponsor**

##### **Name of organization / entity**

Esfahan University of Medical Sciences

##### **Full name of responsible person**

Shaghyegh Haghjoo

##### **Street address**

Hezar Jarib street, Azadi square

##### **City**

Isfahan

##### **Province**

Isfahan

##### **Postal code**

8174673461

##### **Phone**

+98 31 3668 0048

**Email**

research@mui.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

No

**Title of funding source**

Isfahan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact**

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Samira Heydari

**Position**

Medical student/Intern

**Latest degree**

Medical doctor

**Other areas of specialty/work**

General Practitioner

**Street address**

Valiasr Street

**City**

Khorzouq

**Province**

Isfahan

**Postal code**

8345154611

**Phone**

+98 31 4540 6714

**Email**

samiraheydari2525@yahoo.com

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Behzad Nazemroaya

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Hezarjarib Street

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8146713543

**Phone**

+98 31 3620 2020

**Email**

behzad\_nazem@med.mui.ac.ir

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Samira Heydari

**Position**

Medical student/Intern

**Latest degree**

Medical doctor

**Other areas of specialty/work**

General Practitioner

**Street address**

Valiasr Street

**City**

Khorzouq

**Province**

Isfahan

**Postal code**

8345154611

**Phone**

+98 31 4540 6714

**Email**

samiraheydari2525@yahoo.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available